Skip to content

Effect of acupuncture on fMRI and Iowa Gambling Task (IGT) in postherpetic neuralgia (PHN) patients

A clinical study of the effect of acupuncture on fMRI and IGT in postherpetic neuralgia patients: a prospective, double-blind, randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN83626912
Enrollment
38
Registered
2011-10-27
Start date
2011-12-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postherpetic neuralgia Mental and Behavioural Disorders Cranial nerve disorders in diseases classified elsewhere

Interventions

PHN patients were randomized to receive acupuncture (Ashi point), or sham acupuncture for 3 weeks Rescue medication - Oxycodone 5-30mg/day orally (or more) was used as rescue medication for pain cont

Sponsors

Shanghai Sixth People's Hospital (China)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age greater than 60 years 2. Weighs over 40kg 3. History of pain is longer than 3 months 4. Pain on Visual Analogue Scale (VAS) >3 (0-10 VAS scale), with acute pain flares that occurred more than 3 times per day 5. Refractory to formal treatment such as antiepileptic medicine, antidepressants, opioids, physical treatments and epidural block 6. No history of severe liver and renal diseases 7. PHN patents whose pain area was at T1-12 level 8. Male and female participants

Exclusion criteria

Exclusion criteria: 1. Withdraws from the study 2. Poor effect, intolerant to the study 3. Uncooperative and unable to finish the self evaluation (VAS, QOL and SF-36) 4. Coagulation disturbances 5. Allergies to drug 6. Malignancy

Design outcomes

Primary

MeasureTime frame
1. fMRI signal change, IGT results at baseline and 14 days after treatment 2. Visual Analogue Scale (VAS), measured at baseline and 1, 2, 3,7 and 14 days after treatment 3. Pain flare-ups per day during days 3, 7, 14 after treatment

Secondary

MeasureTime frame
1. SF-36 at baseline, 14 days after treatment 2. Dosage of rescue drug (Oxycodone) consumed per day at 3, 7, and 14 days after treatment 3. Presence, frequency and duration of adverse effects at 7 and 14 days after treatment

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026